<DOC>
	<DOCNO>NCT02277522</DOCNO>
	<brief_summary>Pilot open-label study estimate feasibility , safety efficacy intravenously administer , RNA electroporated autologous T cell express CD19 chimeric antigen receptor express tandem TCR 4-1BB ( TCR /4-1BB ) costimulatory domain ( refer RNA CART19 ) Hodgkin Lymphoma ( HL ) patient .</brief_summary>
	<brief_title>CD19 Redirected Autologous T Cells Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Male female subject HL available curative treatment option ( autologous SCT ) limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol . i. HL biopsyproven relapse refractory disease unresponsive intolerant least one line standard salvage therapy ii . Patients must evaluable disease radiologic imaging ( FDG PET/CT PET/MRI ) within 42 day enrollment ; evaluable include assessable and/or measurable disease define Cheson et al. , 2007 . Age ≥ 18 year age Creatinine &lt; 1.6 mg/dl . ALT/AST &lt; 3x upper limit normal Bilirubin &lt; 2.0 mg/dl , unless subject Gilbert 's syndrome ( ≤3.0 mg/dL ) Patients relapsed disease prior allogeneic SCT ( myeloablative nonmyeloablative ) eligible meet inclusion criterion 1 . Have active GVHD require immunosuppression 2 . Are 6 month transplant Performance status ( ECOG ) 0 1 . Left Ventricular Ejection Fraction ( LVEF ) ≥ 40 % confirm ECHO/MUGA Must minimum level pulmonary reserve define ≤ Grade 1 dyspnea pulse oxygen &gt; 92 % room air Written inform consent give . Successful T cell test expansion ( perform part inclusion criterion 3 subject meet enrollment criterion ) Pregnant lactate woman . The safety therapy unborn child know . Female study participant reproductive potential must negative serum pregnancy test enrollment . A urine serum pregnancy test perform within 72 hour first RNA CART19 infusion . Uncontrolled active infection . Active hepatitis B hepatitis C infection . Any uncontrolled active medical disorder would preclude participation outline . HIV infection . Patients known history prior diagnosis optic neuritis immunologic inflammatory disease affect central nervous system Patients active CNS involvement malignancy . Patients prior CNS disease effectively treat eligible provide treatment &gt; 4 week enrollment Patients complete remission evidence evaluable disease radiologic image . History allergy murine protein . History allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) . AntiCD20 monoclonal antibody therapy within last 3 month , absence circulating B cell . Class III/IV cardiovascular disability accord New York Heart Association Classification ( see Appendix 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>